

# Elizabeth A Evans

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4061278/publications.pdf>

Version: 2024-02-01

88  
papers

3,215  
citations

147801

31  
h-index

168389

53  
g-index

90  
all docs

90  
docs citations

90  
times ranked

3536  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Course of Opioid Addiction. <i>Harvard Review of Psychiatry</i> , 2015, 23, 76-89.	2.1	212
2	Relationship Between Drug Treatment Services, Retention, and Outcomes. <i>Psychiatric Services</i> , 2004, 55, 767-774.	2.0	209
3	Treatment outcomes among women and men methamphetamine abusers in California. <i>Journal of Substance Abuse Treatment</i> , 2005, 28, 77-85.	2.8	169
4	Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. <i>Addiction</i> , 2016, 111, 695-705.	3.3	165
5	Benefit-Cost in the California Treatment Outcome Project: Does Substance Abuse Treatment "Pay for Itself"? <i>Health Services Research</i> , 2006, 41, 192-213.	2.0	140
6	Contrasting Trajectories of Heroin, Cocaine, and Methamphetamine Use. <i>Journal of Addictive Diseases</i> , 2008, 27, 13-21.	1.3	106
7	Client and program factors associated with dropout from court mandated drug treatment. <i>Evaluation and Program Planning</i> , 2009, 32, 204-212.	1.6	102
8	Polydrug use and implications for longitudinal research: Ten-year trajectories for heroin, cocaine, and methamphetamine users. <i>Drug and Alcohol Dependence</i> , 2008, 96, 193-201.	3.2	94
9	Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10. <i>Addiction</i> , 2015, 110, 996-1005.	3.3	93
10	Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. <i>International Journal of Drug Policy</i> , 2017, 49, 32-40.	3.3	87
11	Comparing the dynamic course of heroin, cocaine, and methamphetamine use over 10 years. <i>Addictive Behaviors</i> , 2008, 33, 1581-1589.	3.0	75
12	Accuracy of amplitude integrated EEG in a neonatal cohort. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2010, 95, F169-F173.	2.8	66
13	Gender and race/ethnic differences in the persistence of alcohol, drug, and poly-substance use disorders. <i>Drug and Alcohol Dependence</i> , 2017, 174, 128-136.	3.2	63
14	Effects of a randomized contingency management intervention on opiate abstinence and retention in methadone maintenance treatment in China. <i>Addiction</i> , 2011, 106, 1801-1809.	3.3	62
15	Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study. <i>Addiction</i> , 2012, 107, 1621-1629.	3.3	59
16	Using Administrative Data for Longitudinal Substance Abuse Research. <i>Journal of Behavioral Health Services and Research</i> , 2010, 37, 252-271.	1.4	56
17	Impact of California's Proposition 36 on the Drug Treatment System: Treatment Capacity and Displacement. <i>American Journal of Public Health</i> , 2007, 97, 104-109.	2.7	53
18	Employment trajectories: Exploring gender differences and impacts of drug use. <i>Journal of Vocational Behavior</i> , 2011, 79, 277-289.	3.4	50

#	ARTICLE	IF	CITATIONS
19	Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial. <i>Journal of NeuroImmune Pharmacology</i> , 2018, 13, 488-497.	4.1	50
20	The Effects of Opioid Substitution Treatment and Highly Active Antiretroviral Therapy on the Cause-Specific Risk of Mortality Among HIV-Positive People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2015, 61, 1157-1165.	5.8	48
21	Cost-Effectiveness of Publicly Funded Treatment of Opioid Use Disorder in California. <i>Annals of Internal Medicine</i> , 2018, 168, 10.	3.9	43
22	Cross-system data linkage for treatment outcome evaluation: Lessons learned from the California Treatment Outcome Project. <i>Evaluation and Program Planning</i> , 2008, 31, 125-135.	1.6	42
23	Outcomes of Drug and Alcohol Treatment Programs Among American Indians in California. <i>American Journal of Public Health</i> , 2006, 96, 889-896.	2.7	40
24	Maternal Mental Health and Children's Internalizing and Externalizing Behaviors: Beyond Maternal Substance Use Disorders. <i>Journal of Child and Family Studies</i> , 2015, 24, 638-648.	1.3	40
25	Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2022, 231, 109254.	3.2	40
26	Treating Drug-Abusing Offenders. <i>Evaluation Review</i> , 2003, 27, 479-505.	1.0	39
27	Long-term outcomes among drug-dependent mothers treated in women-only versus mixed-gender programs. <i>Journal of Substance Abuse Treatment</i> , 2011, 41, 115-123.	2.8	39
28	Gender differences in mortality among treated opioid dependent patients. <i>Drug and Alcohol Dependence</i> , 2015, 155, 228-235.	3.2	39
29	The costs of crime during and after publicly funded treatment for opioid use disorders: a population-level study for the state of California. <i>Addiction</i> , 2017, 112, 838-851.	3.3	37
30	Mortality among substance-using mothers in California: a 10-year prospective study. <i>Addiction</i> , 2012, 107, 215-222.	3.3	36
31	Childhood adversity and mental health comorbidity in men and women with opioid use disorders. <i>Addictive Behaviors</i> , 2020, 102, 106149.	3.0	36
32	Gender differences in the effects of childhood adversity on alcohol, drug, and polysubstance-related disorders. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2017, 52, 901-912.	3.1	34
33	Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder. <i>Addiction</i> , 2019, 114, 1396-1404.	3.3	32
34	Gender Differences in Use of Complementary and Integrative Health by U.S. Military Veterans with Chronic Musculoskeletal Pain. <i>Women's Health Issues</i> , 2018, 28, 379-386.	2.0	31
35	Explaining long-term outcomes among drug dependent mothers treated in women-only versus mixed-gender programs. <i>Journal of Substance Abuse Treatment</i> , 2013, 45, 293-301.	2.8	30
36	Offender Diversion Into Substance Use Disorder Treatment: The Economic Impact of California's Proposition 36. <i>American Journal of Public Health</i> , 2013, 103, 1096-1102.	2.7	29

#	ARTICLE	IF	CITATIONS
37	Utilization and outcomes of detoxification and maintenance treatment for opioid dependence in publicly-funded facilities in California, USA: 1991–2012. <i>Drug and Alcohol Dependence</i> , 2014, 143, 149-157.	3.2	29
38	Pilot-Testing a Statewide Outcome Monitoring System: Overview of the California Treatment Outcome Project (CALTOP). <i>Journal of Psychoactive Drugs</i> , 2004, 36, 109-114.	1.7	28
39	High-Risk Offenders Participating in Court-Supervised Substance Abuse Treatment: Characteristics, Treatment Received, and Factors Associated with Recidivism. <i>Journal of Behavioral Health Services and Research</i> , 2011, 38, 510-525.	1.4	25
40	Differential Outcomes of Court-Supervised Substance Abuse Treatment Among California Parolees and Probationers. <i>International Journal of Offender Therapy and Comparative Criminology</i> , 2012, 56, 539-556.	1.2	25
41	Ethnic differences in utilization of drug treatment services and outcomes among Proposition 36 offenders in California. <i>Journal of Substance Abuse Treatment</i> , 2007, 33, 391-399.	2.8	24
42	Differences by Veteran/civilian status and gender in associations between childhood adversity and alcohol and drug use disorders. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2018, 53, 421-435.	3.1	24
43	Characterizing longitudinal health state transitions among heroin, cocaine, and methamphetamine users. <i>Drug and Alcohol Dependence</i> , 2014, 140, 69-77.	3.2	23
44	Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder. <i>Journal of Substance Abuse Treatment</i> , 2019, 106, 19-28.	2.8	21
45	Developmental timing of first drug treatment and 10-year patterns of drug use. <i>Journal of Substance Abuse Treatment</i> , 2013, 44, 271-279.	2.8	20
46	Massachusetts Justice Community Opioid Innovation Network (MassJOIN). <i>Journal of Substance Abuse Treatment</i> , 2021, 128, 108275.	2.8	20
47	Treatment entry barriers among California's Proposition 36 offenders. <i>Journal of Substance Abuse Treatment</i> , 2008, 35, 410-418.	2.8	19
48	A mixed methods approach to identifying factors related to voluntary HIV testing among injection drug users in Shanghai, China. <i>International Journal of Infectious Diseases</i> , 2012, 16, e498-e503.	3.3	19
49	Comparative Effectiveness of California's Proposition 36 and Drug Court Programs Before and After Propensity Score Matching. <i>Crime and Delinquency</i> , 2014, 60, 909-938.	1.7	19
50	COVID-19 and treating incarcerated populations for opioid use disorder. <i>Journal of Substance Abuse Treatment</i> , 2021, 124, 108216.	2.8	18
51	A Marginal Structural Modeling Approach to Assess the Cumulative Effect of Drug Treatment on Later Drug Use Abstinence. <i>Journal of Drug Issues</i> , 2010, 40, 221-240.	1.2	17
52	Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone. <i>Drug and Alcohol Dependence</i> , 2021, 228, 108996.	3.2	17
53	Children of treated substance-abusing mothers: A 10-year prospective study. <i>Clinical Child Psychology and Psychiatry</i> , 2014, 19, 217-232.	1.6	16
54	Evaluation of the Substance Abuse and Crime Prevention Act: Treatment Clients and Program Types During the First Year of Implementation. <i>Journal of Psychoactive Drugs</i> , 2004, 36, 165-174.	1.7	15

#	ARTICLE	IF	CITATIONS
55	Evaluation of the Substance Abuse and Crime Prevention Act: Client Characteristics, Treatment Completion and Re-Offending Three Years After Implementation. <i>Journal of Psychoactive Drugs</i> , 2006, 38, 357-367.	1.7	15
56	Perceived Neighborhood Safety, Recovery Capital, and Successful Outcomes Among Mothers 10 years After Substance Abuse Treatment. <i>Substance Use and Misuse</i> , 2014, 49, 1491-1503.	1.4	15
57	Utilization and Outcomes of Mental Health Services Among Patients in Drug Treatment. <i>Journal of Addictive Diseases</i> , 2006, 25, 73-85.	1.3	14
58	More Alike than Different: Health Needs, Services Utilization, and Outcomes of Asian American and Pacific Islander (AAPI) Populations Treated for Substance Use Disorders. <i>Journal of Ethnicity in Substance Abuse</i> , 2012, 11, 318-338.	0.9	14
59	Predictors of short-term treatment outcomes among California's Proposition 36 participants. <i>Evaluation and Program Planning</i> , 2007, 30, 187-196.	1.6	13
60	Promising practices for delivery of court-supervised substance abuse treatment: Perspectives from six high-performing California counties operating Proposition 36. <i>Evaluation and Program Planning</i> , 2011, 34, 124-134.	1.6	13
61	Why Women Veterans Do Not Use VA-Provided Health and Social Services: Implications for Health Care Design and Delivery. <i>Journal of Humanistic Psychology</i> , 2024, 64, 251-280.	2.1	13
62	Longitudinal HIV Risk Behavior Among the Drug Abuse Treatment Outcome Studies (DATOS) Adult Sample. <i>Evaluation Review</i> , 2008, 32, 83-112.	1.0	12
63	Employment Services Utilization and Outcomes among Substance Abusing Offenders Participating in California's Proposition 36 Drug Treatment Initiative. <i>Journal of Behavioral Health Services and Research</i> , 2010, 37, 461-476.	1.4	12
64	Hepatitis C among methadone maintenance treatment patients in Shanghai and Kunming, China. <i>Journal of Public Health</i> , 2012, 34, 24-31.	1.8	12
65	Risk Factors Associated with HCV Among Opioid-Dependent Patients in a Multisite Study. <i>Journal of Community Health</i> , 2015, 40, 940-947.	3.8	12
66	Estimating State Transitions for Opioid Use Disorders. <i>Medical Decision Making</i> , 2017, 37, 483-497.	2.4	12
67	Legislatively mandated implementation of medications for opioid use disorders in jails: A qualitative study of clinical, correctional, and jail administrator perspectives. <i>Drug and Alcohol Dependence</i> , 2022, 234, 109394.	3.2	12
68	Heterogeneity of Mental Health Service Utilization and High Mental Health Service Use Among Women Eight Years After Initiating Substance Use Disorder Treatment. <i>Journal of Substance Abuse Treatment</i> , 2015, 59, 10-19.	2.8	11
69	A qualitative study of big data and the opioid epidemic: recommendations for data governance. <i>BMC Medical Ethics</i> , 2020, 21, 101.	2.4	11
70	Implementation of a Statewide Outcome Monitoring System: Lessons Learned From Substance Abuse Treatment Provider Staff. <i>Qualitative Health Research</i> , 2006, 16, 337-352.	2.1	10
71	Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail. <i>Journal of Substance Abuse Treatment</i> , 2022, 138, 108746.	2.8	10
72	Predictors of Intention to Change HIV Sexual and Injection Risk Behaviors among Heterosexual Methamphetamine-Using Offenders in Drug Treatment: A Test of the AIDS Risk Reduction Model. <i>Journal of Behavioral Health Services and Research</i> , 2009, 36, 247-266.	1.4	9

#	ARTICLE	IF	CITATIONS
73	Are There Gender Differences in Arrest Trajectories among Adult Drug Abuse Treatment Participants?. <i>Journal of Drug Issues</i> , 2010, 40, 7-26.	1.2	9
74	Psychosocial Factors that Shape Substance Abuse and Related Mental Health of Women Military Veterans who Use Community-Based Services. <i>Substance Use and Misuse</i> , 2018, 53, 1878-1892.	1.4	8
75	Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial. <i>Addiction</i> , 2022, 117, 151-161.	3.3	8
76	Regulatory Issues Encountered When Conducting Longitudinal Substance Abuse Research. <i>Journal of Drug Issues</i> , 2008, 38, 1003-1025.	1.2	6
77	Changes in Medicaid Acceptance by Substance Abuse Treatment Facilities After Implementation of Federal Parity. <i>Medical Care</i> , 2020, 58, 101-107.	2.4	6
78	Perceived Benefits and Harms of Involuntary Civil Commitment for Opioid Use Disorder. <i>Journal of Law, Medicine and Ethics</i> , 2020, 48, 718-734.	0.9	6
79	Consistency in Self-Reports of Drug Use Frequency by High-Risk Offenders Over a 5-Year Interval. <i>Prison Journal</i> , 2013, 93, 375-389.	0.7	5
80	Prevalence and Correlates of Cannabis Use in Massachusetts after Cannabis Legalization and before Retail Sales. <i>Journal of Psychoactive Drugs</i> , 2021, 53, 158-167.	1.7	4
81	A Scoping Review of Data Sources for the Conduct of Policy-Relevant Substance Use Research. <i>Public Health Reports</i> , 2022, 137, 944-954.	2.5	4
82	The Natural History, Clinical Course, and Long-Term Recovery from Opioid Use Disorders. <i>Current Clinical Psychiatry</i> , 2019, , 181-196.	0.2	4
83	Commentary on Degenhardt <i>et al</i> . (2014): Regional variation in the global burden of disease attributable to opioid dependence—where do the data come from and does population size matter?. <i>Addiction</i> , 2014, 109, 1334-1335.	3.3	3
84	Predictors of Functioning and Recovery Among Men and Women Veterans with Schizophrenia. <i>Community Mental Health Journal</i> , 2023, 59, 110-121.	2.0	2
85	The Massachusetts public health data warehouse and the opioid epidemic: A qualitative study of perceived strengths and limitations for advancing research. <i>Preventive Medicine Reports</i> , 2022, 28, 101847.	1.8	2
86	How Can Research-Based Findings Be Used to Improve Practice? Perspectives from Participants in a Statewide Outcomes Monitoring Study. <i>Journal of Drug Issues</i> , 2005, 35, 469-483.	1.2	1
87	Hispanic parenting women in women-only versus mixed-gender drug treatment: A 10-year prospective study. <i>Addictive Behaviors</i> , 2012, 37, 729-735.	3.0	1
88	Commentary on Adams <i>et al</i> .: using administrative big data for the public good. <i>Addiction</i> , 0, , .	3.3	1